The road from development to approval: evaluating the body of evidence to confirm biosimilarity-Reference-Cited by-同舟云学术

The road from development to approval: evaluating the body of evidence to confirm biosimilarity

Published:2017-08-01 Issue:suppl_4 Volume:56 Page:iv4-iv13
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Declerck Paul¹^ORCID,Farouk Rezk Mourad²

Affiliation:

1. Laboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven – University of Leuven, Leuven, Belgium

2. Biogen International GmbH, Zug, Switzerland

Funder

Biogen

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/56/suppl_4/iv4/24245951/kex279.pdf

Reference57 articles.

1. Biosimilar drugs: current status;Kumar;Int J Appl Basic Med Res,2014

2. Biosimilar monoclonal antibodies: a science-based regulatory challenge;Declerck;Expert Opin Biol Ther,2013

3. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective;Vincent;Ann Rheum Dis,2013

4. Biologic therapy for autoimmune diseases: an update;Rosman;BMC Med,2013

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vergleich von Trastuzumab-Biosimilar ABP 980 mit Referenz-Trastuzumab bei der neoadjuvanten Therapie von HER2-positivem Brustkrebs – Analyse eines großen universitären Brustkrebszentrums;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-05-23

2. INVESTIGATING THE PHYSICOCHEMICAL, NON-CLINICAL, AND CLINICAL CRITERIA FOR ASSESSING COMPARABILITY IN RANIBIZUMAB BIOSIMILARS: A COMPREHENSIVE REVIEW;FARMACIA;2024

3. An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare;Pharmaceuticals;2024-02-11

4. Biosimilars: Principles, Regulatory Framework, and Societal Aspects;Pharmaceutical Biotechnology;2024

5. Biosimilars in Gastric Cancer;Biosimilars for Cancer Treatment;2024